Santen and IAPB Partner to Advocate for Better Eye Health
Notice of Commencement of Preparation for Transition to a Holding Company Structure through Sole-Share Transfer and Change in Fiscal Year
Santen Reports the 3rd Quarter Fiscal 2020 Consolidated Performance
(Timely Disclosure) Notice of Commencement of Preparation for Transition to a Holding Company and Change in Fiscal Year
Santen and Ube Announces U.S. FDA Acceptance of New Drug Application for STN10117 (DE-117) (JAN: Omidenepag Isopropyl) as a Treatment for Patients with Glaucoma and Ocular Hypertension
Santen and Ube Announces Launch of Glaucoma and Ocular Hypertension Treatment EYBELIS Ophthalmic Solution 0.002% in South Korea
Corporate Social Responsibility (CSR) page on our website has been updated
Santen Joins the Valuable 500 International Initiative Promoting the Active Participation of People with Disabilities
